155290-47-4 Usage
Description
2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID is a versatile chemical compound that features a BOC (tert-butyloxycarbonyl) protected hydrazino moiety attached to a benzoic acid structure. 2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID is characterized by its ability to undergo mild deprotection of the BOC group, revealing a reactive hydrazino group that can be utilized in various chemical transformations, such as coupling reactions, to synthesize complex molecules. The benzoic acid component further enhances its reactivity and applicability in organic synthesis, making it a valuable building block in the development of peptide-based drugs and drug candidates.
Uses
Used in Pharmaceutical Synthesis:
2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID is used as a key intermediate in the synthesis of peptide-based drugs or drug candidates. The BOC protecting group allows for mild deprotection conditions, enabling the exposure of the reactive hydrazino group for subsequent chemical reactions, such as coupling, to form complex molecular structures.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID serves as a versatile building block. The benzoic acid moiety can participate in various chemical reactions, providing a foundation for the creation of diverse chemical entities with potential applications in different industries.
Used in Chemical Research:
2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID is utilized in chemical research for exploring novel synthetic pathways and methodologies. Its unique structure and reactivity make it an attractive candidate for studying new chemical transformations and understanding the underlying mechanisms of various reactions.
Used in Drug Development:
In the drug development industry, 2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID is employed as a precursor in the synthesis of potential drug molecules. Its ability to undergo selective deprotection and subsequent reactions allows for the creation of bioactive compounds with therapeutic potential.
Overall, 2-(2'-N-BOC-HYDRAZINO)BENZOIC ACID is a multifaceted chemical compound with applications spanning across various fields, including pharmaceutical synthesis, organic synthesis, chemical research, and drug development. Its unique structure and reactivity make it an indispensable tool in the hands of chemists and researchers working towards the discovery and development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 155290-47-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,5,2,9 and 0 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 155290-47:
(8*1)+(7*5)+(6*5)+(5*2)+(4*9)+(3*0)+(2*4)+(1*7)=134
134 % 10 = 4
So 155290-47-4 is a valid CAS Registry Number.
155290-47-4Relevant articles and documents
SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
-
Page/Page column 119-120, (2019/05/15)
Substituted triazole derivatives and uses thereof The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
Structure-activity relationships of a series of substituted benzamides: Potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents
Norman, Mark H.,Rigdon, Greg C.,Hall, William R.,Navas III, Frank
, p. 1172 - 1188 (2007/10/03)
A series of substituted (4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide derivatives was prepared and evaluated as potential atypical antipsychotic agents. The target compounds were readily prepared from their benzoyl chloride, benzoic acid, or isatoic anhydride precursors, and they were evaluated in vitro for their ability to bind to dopamine D2, serotonin 5-HT2, and serotonin 5-HT1a receptors. To assess the potential antipsychotic activity of these compounds, we investigated their ability to inhibit the apomorphine-induced climbing response in mice. Selected compounds were evaluated further to determine their side-effect potentials. Structure-activity relationships of both mono- and polysubstituted benzamides are discussed herein. While several analogues had potent in vitro and in vivo activities indicative of potential atypical antipsychotic activity, anthranilamide 77 (1192U90) demonstrated a superior pharmacological profile. As a result of this investigation, 1192U90 (2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide hydrochloride) was selected for further evaluation and is currently in phase I clinical trials as a potential atypical antipsychotic agent.
